Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1998 1
2005 1
2006 2
2008 3
2009 4
2010 5
2011 3
2012 21
2013 19
2014 38
2015 59
2016 81
2017 87
2018 120
2019 162
2020 196
2021 184
2022 182
2023 147
2024 65

Text availability

Article attribute

Article type

Publication date

Search Results

1,191 results

Results by year

Filters applied: . Clear all
Page 1
Apremilast in dermatology: A review of literature.
Nassim D, Alajmi A, Jfri A, Pehr K. Nassim D, et al. Dermatol Ther. 2020 Nov;33(6):e14261. doi: 10.1111/dth.14261. Epub 2020 Sep 27. Dermatol Ther. 2020. PMID: 32876993 Review.
Apremilast is an orally administered small molecule that specifically inhibits the phosphodiesterase-4 enzyme and modulates the immune system by increasing the levels of intracellular cyclic adenosine monophosphate (cAMP) and inhibiting IL-2 & 8, interferon-gamma and t …
Apremilast is an orally administered small molecule that specifically inhibits the phosphodiesterase-4 enzyme and modulates the immun …
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. Strober B, et al. J Am Acad Dermatol. 2023 Jan;88(1):40-51. doi: 10.1016/j.jaad.2022.08.061. Epub 2022 Sep 14. J Am Acad Dermatol. 2023. PMID: 36115523 Free article. Clinical Trial.
METHODS: POETYK psoriasis second trial (NCT03611751), a 52-week, double-blinded, phase 3 trial, randomized patients 2:1:1 to deucravacitinib 6 mg every day (n = 511), placebo (n = 255), or apremilast 30 mg twice a day (n = 254). RESULTS: At week 16, significantly more deuc …
METHODS: POETYK psoriasis second trial (NCT03611751), a 52-week, double-blinded, phase 3 trial, randomized patients 2:1:1 to deucravacitinib …
Apremilast for psoriasis treatment.
Carrascosa JM, Del-Alcazar E. Carrascosa JM, et al. G Ital Dermatol Venereol. 2020 Aug;155(4):421-433. doi: 10.23736/S0392-0488.20.06684-5. Epub 2020 Jun 15. G Ital Dermatol Venereol. 2020. PMID: 32545946 Free article. Review.
Efficacy of apremilast in moderate-to-severe psoriasis has been demonstrated in the pivotal trials, with a 30% PASI-75 response rate at week 16, an efficacy that was maintained through week 52. Apremilast also achieved significant responses in disease involving spec …
Efficacy of apremilast in moderate-to-severe psoriasis has been demonstrated in the pivotal trials, with a 30% PASI-75 response rate …
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA. Stein Gold LF, et al. Br J Dermatol. 2023 Oct 25;189(5):540-552. doi: 10.1093/bjd/ljad252. Br J Dermatol. 2023. PMID: 37488811 Clinical Trial.
The enrolled patients (randomized 1 : 2) received subcutaneous risankizumab (150 mg at weeks 0 and 4) or oral apremilast (30 mg twice daily). At week 16, all patients treated with apremilast were re-randomized (1 : 1) to risankizumab or apremilast, stratified …
The enrolled patients (randomized 1 : 2) received subcutaneous risankizumab (150 mg at weeks 0 and 4) or oral apremilast (30 mg twice …
Apremilast and its role in psoriatic arthritis.
Sandhu VK, Eder L, Yeung J. Sandhu VK, et al. G Ital Dermatol Venereol. 2020 Aug;155(4):386-399. doi: 10.23736/S0392-0488.20.06640-7. G Ital Dermatol Venereol. 2020. PMID: 33050680 Free article. Review.
Efficacy was limited in patients with previous biologic DMARD failure and the overall efficacy of apremilast appears to be less than biologics agents, though no head-to-head trials exist comparing apremilast to biologic DMARDs. ...More studies directly comparing …
Efficacy was limited in patients with previous biologic DMARD failure and the overall efficacy of apremilast appears to be less than …
Apremilast Uses and Relevance to the Military.
Hathaway NE, Lyford WH. Hathaway NE, et al. Cutis. 2021 Apr;107(4):216-220. doi: 10.12788/cutis.0231. Cutis. 2021. PMID: 34096849 Review.
In this article, we review on-label indications and off-label uses for apremilast; highlight the importance of apremilast for managing psoriasis in the military population; and propose other patient populations in whom the use of apremilast is favorable. We a …
In this article, we review on-label indications and off-label uses for apremilast; highlight the importance of apremilast for …
Preclinical and clinical evidence for suppression of alcohol intake by apremilast.
Grigsby KB, Mangieri RA, Roberts AJ, Lopez MF, Firsick EJ, Townsley KG, Beneze A, Bess J, Eisenstein TK, Meissler JJ, Light JM, Miller J, Quello S, Shadan F, Skinner M, Aziz HC, Metten P, Morrisett RA, Crabbe JC, Roberto M, Becker HC, Mason BJ, Ozburn AR. Grigsby KB, et al. J Clin Invest. 2023 Mar 15;133(6):e159103. doi: 10.1172/JCI159103. J Clin Invest. 2023. PMID: 36656645 Free PMC article. Clinical Trial.
Apremilast also reduced excessive alcohol drinking in models of stress-facilitated drinking and alcohol dependence. ...These results demonstrate that apremilast suppresses excessive alcohol drinking across the spectrum of AUD severity....
Apremilast also reduced excessive alcohol drinking in models of stress-facilitated drinking and alcohol dependence. ...These results …
Evolving utility of apremilast in dermatological disorders for off-label indications.
Mehta H, Sharma A, Dogra S. Mehta H, et al. Clin Exp Dermatol. 2022 Dec;47(12):2136-2149. doi: 10.1111/ced.15377. Epub 2022 Oct 8. Clin Exp Dermatol. 2022. PMID: 35974705 Review.
This review was carried out with the aim of summarizing the literature on off-label use of apremilast in dermatology, in order to guide clinicians regarding currently available evidence. The PubMed database was searched using 'apremilast' as a keyword in the title. …
This review was carried out with the aim of summarizing the literature on off-label use of apremilast in dermatology, in order to gui …
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Papp K, et al. J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049. J Am Acad Dermatol. 2015. PMID: 26089047 Free article. Clinical Trial.
BACKGROUND: Apremilast works intracellularly to regulate inflammatory mediators. ...CONCLUSIONS: Apremilast was effective in moderate to severe plaque psoriasis....
BACKGROUND: Apremilast works intracellularly to regulate inflammatory mediators. ...CONCLUSIONS: Apremilast was effective in m …
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behcet's Syndrome.
Mease PJ, Hatemi G, Paris M, Cheng S, Maes P, Zhang W, Shi R, Flower A, Picard H, Stein Gold L. Mease PJ, et al. Am J Clin Dermatol. 2023 Sep;24(5):809-820. doi: 10.1007/s40257-023-00783-7. Epub 2023 Jun 14. Am J Clin Dermatol. 2023. PMID: 37316690 Free PMC article.
OBJECTIVE: The aim of this study was to conduct a pooled analysis of apremilast data from 15 clinical studies with open-label extension phases, focusing on long-term safety. ...RESULTS: Overall, 4183 patients were exposed to apremilast (6788 patient-years). Most TEA …
OBJECTIVE: The aim of this study was to conduct a pooled analysis of apremilast data from 15 clinical studies with open-label extensi …
1,191 results

Searches related to "apremilast"